文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

脂蛋白(a)水平升高、LPA 风险基因型与普通人群心力衰竭风险增加。

Elevated Lipoprotein(a) Levels, LPA Risk Genotypes, and Increased Risk of Heart Failure in the General Population.

机构信息

Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Copenhagen, Denmark; The Copenhagen General Population Study, Herlev Hospital, Copenhagen University Hospital, Copenhagen, Denmark; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Copenhagen, Denmark; The Copenhagen General Population Study, Herlev Hospital, Copenhagen University Hospital, Copenhagen, Denmark; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; The Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen University Hospital, Copenhagen, Denmark.

出版信息

JACC Heart Fail. 2016 Jan;4(1):78-87. doi: 10.1016/j.jchf.2015.08.006. Epub 2015 Dec 2.


DOI:10.1016/j.jchf.2015.08.006
PMID:26656145
Abstract

OBJECTIVES: This study sough to test whether elevated lipoprotein(a) levels and corresponding LPA risk genotypes (low number of kringle IV type 2 repeats, rs3798220 and rs10455872, minor allele carriers) are associated with an increased risk of heart failure (HF). BACKGROUND: Elevated lipoprotein(a) levels represent a genetically determined risk factor for myocardial infarction (MI) and aortic valve stenosis (AVS). It is presently unknown whether elevated lipoprotein(a) levels also cause heart failure (HF). METHODS: We combined 2 general population studies, the Copenhagen City Heart Study (n = 10,855) and the Copenhagen General Population Study (n = 87,242), which totaled 98,097 Danish participants, of whom 4,122 were diagnosed with HF (1976 to 2013). We conducted observational and genetic instrumental variable analyses in a Mendelian randomization study design, assessing evidence of causality, and we performed mediation analyses. RESULTS: Elevated lipoprotein(a) levels were associated with multivariable adjusted hazard ratios for HF of 1.10 (95% CI: 0.97 to 1.25) for the 34th to 66th percentiles (8 to 19 mg/dl), 1.24 (95% CI: 1.08 to 1.42) for the 67th to 90th percentiles (20 to 67 mg/dl), 1.57 (95% CI: 1.32 to 1.87) for the 91st to 99th percentiles (68 to 153 mg/dl), and 1.79 (95% CI: 1.18 to 2.73) for levels >99th percentile (>153 mg/dl) versus levels <34th percentile (<8 mg/dl) (trend, p < 0.001), corresponding to a population-attributable risk of 9%. By combining all LPA risk genotypes, instrumental variable analysis yielded a genetic relative risk for HF of 1.18 (95% CI: 1.04 to 1.34) per 10-fold higher lipoprotein(a) levels, which was comparable to the corresponding observational hazard ratio of 1.22 (95% CI: 1.11 to 1.35). Upon exclusion of participants diagnosed with MI or AVS, risk estimates were attenuated. Accordingly, 63% (95% CI: 45% to 99%) of HF risk was mediated via MI and AVS combined. CONCLUSIONS: Elevated lipoprotein(a) levels and corresponding LPA risk genotypes were associated with an increased risk of HF consistent with a causal association. The association appeared to be partly mediated by MI and AVS.

摘要

目的:本研究旨在检验脂蛋白(a)水平升高及其相应的 LPA 风险基因型(kringle IV 型 2 重复次数较少、rs3798220 和 rs10455872 、次要等位基因携带者)是否与心力衰竭(HF)风险增加相关。

背景:脂蛋白(a)水平升高是心肌梗死(MI)和主动脉瓣狭窄(AVS)的遗传决定因素。目前尚不清楚脂蛋白(a)水平升高是否也会导致心力衰竭(HF)。

方法:我们结合了两项一般人群研究,哥本哈根城市心脏研究(n=10855)和哥本哈根一般人群研究(n=87242),共有 98097 名丹麦参与者,其中 4122 人被诊断为 HF(1976 年至 2013 年)。我们在孟德尔随机化研究设计中进行了观察性和遗传工具变量分析,评估因果关系的证据,并进行了中介分析。

结果:脂蛋白(a)水平升高与多变量调整后的 HF 风险比相关,第 34 至 66 百分位(8 至 19mg/dl)为 1.10(95%CI:0.97 至 1.25),第 67 至 90 百分位(20 至 67mg/dl)为 1.24(95%CI:1.08 至 1.42),第 91 至 99 百分位(68 至 153mg/dl)为 1.57(95%CI:1.32 至 1.87),第 99 百分位以上(153mg/dl 以上)与第 34 百分位以下(8mg/dl 以下)相比,风险比为 1.79(95%CI:1.18 至 2.73)(趋势,p<0.001),对应 9%的人群归因风险。通过结合所有 LPA 风险基因型,工具变量分析得出 HF 的遗传相对风险为脂蛋白(a)水平每升高 10 倍增加 1.18(95%CI:1.04 至 1.34),与相应的观察性危险比 1.22(95%CI:1.11 至 1.35)相当。排除 MI 或 AVS 诊断的参与者后,风险估计值减弱。因此,HF 风险的 63%(95%CI:45%至 99%)通过 MI 和 AVS 联合介导。

结论:脂蛋白(a)水平升高及其相应的 LPA 风险基因型与 HF 风险增加相关,与因果关系一致。这种关联似乎部分是通过 MI 和 AVS 介导的。

相似文献

[1]
Elevated Lipoprotein(a) Levels, LPA Risk Genotypes, and Increased Risk of Heart Failure in the General Population.

JACC Heart Fail. 2015-12-2

[2]
Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population.

J Am Coll Cardiol. 2013-10-23

[3]
Elevated Lipoprotein(a) Does Not Cause Low-Grade Inflammation Despite Causal Association With Aortic Valve Stenosis and Myocardial Infarction: A Study of 100,578 Individuals from the General Population.

J Clin Endocrinol Metab. 2015-5-4

[4]
Genetically elevated lipoprotein(a) and increased risk of myocardial infarction.

JAMA. 2009-6-10

[5]
Oxidized Phospholipids and Risk of Calcific Aortic Valve Disease: The Copenhagen General Population Study.

Arterioscler Thromb Vasc Biol. 2017-8

[6]
Extreme lipoprotein(a) levels and improved cardiovascular risk prediction.

J Am Coll Cardiol. 2013-1-30

[7]
Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study.

Lancet Diabetes Endocrinol. 2013-8-27

[8]
Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study.

Circulation. 2008-1-15

[9]
No evidence that genetically reduced 25-hydroxyvitamin D is associated with increased risk of ischaemic heart disease or myocardial infarction: a Mendelian randomization study.

Int J Epidemiol. 2015-5-16

[10]
Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort.

Circ Cardiovasc Genet. 2014-6

引用本文的文献

[1]
Assessment of the Utilization of Lipoprotein (a) and its Relationship with Cardiovascular Outcomes: A Retrospective Cohort Study from a Public Hospital in New York City.

Heart Views. 2025

[2]
The effect of medroxyprogesterone acetate plus conjugated equine estrogens on lipoprotein(a) and apolipoprotein concentrations in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials.

Diabetol Metab Syndr. 2025-7-28

[3]
Lp(a) in daily clinical routine: risk-factor for both cardiovascular events and heart-failure? A retrospective analysis of the Luebeck Lp(a) heart-failure (HF) registry in patients after myocardial infarction.

Atheroscler Plus. 2025-7-12

[4]
Lipoprotein(a): Assessing the Current Knowledge and Gaps in Screening and Treatment-A Narrative Review.

J Cardiovasc Dev Dis. 2025-4-26

[5]
Lipoprotein(a) and Heart Failure Among Black and White Participants in Atherosclerosis Risk in Communities Study, Framingham Offspring Study, and Multi-Ethnic Study of Atherosclerosis: The Pooling Project.

J Am Heart Assoc. 2025-6-3

[6]
Lipoprotein(a) and panvascular disease.

Lipids Health Dis. 2025-5-24

[7]
2024: The year in cardiovascular disease - the year of lipoprotein(a). Research advances and new findings.

Arch Med Sci. 2025-2-22

[8]
Lipoprotein(a) Levels and Adverse Outcomes in Heart Failure.

J Card Fail. 2025-4-4

[9]
Elevated Lp(a) and its association with cardiac fibrosis in group II pulmonary hypertension patients.

Future Cardiol. 2025-2

[10]
Mendelian randomization analysis does not support a causal influence between lipoprotein(A) and immune-mediated inflammatory diseases.

Sci Rep. 2025-1-30

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索